Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017:2017:4895736.
doi: 10.1155/2017/4895736. Epub 2017 Mar 20.

Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction

Shih Yea Sylvia Wu  1 , Bridget Faire  1 , Edward Gane  1
Affiliations
Case Reports

Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction

Shih Yea Sylvia Wu et al. Case Rep Med. 2017.

Abstract

VIEKIRA PAK (ritonavir-boosted paritaprevir/ombitasvir and dasabuvir) is an approved treatment for compensated patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This oral regimen has minimal adverse effects and is well tolerated. Cure rates are 97% in patients infected with HCV GT 1a and 99% in those with HCV GT 1b. We report the first case of life-threatening allergic pneumonitis associated with VIEKIRA PAK. This unexpected serious adverse event occurred in a 68-year-old Chinese female with genotype 1b chronic hepatitis C and Child-Pugh A cirrhosis. One week into treatment with VIEKIRA PAK without ribavirin, she was admitted to hospital with respiratory distress and acute kidney injury requiring intensive care input. She was initially diagnosed with community acquired pneumonia and improved promptly with intravenous antibiotics and supported care. No bacterial or viral pathogens were cultured. Following complete recovery, she recommenced VIEKIRA PAK but represented 5 days later with more rapidly progressive respiratory failure, requiring intubation and ventilation, inotropic support, and haemodialysis. The final diagnosis was drug induced pneumonitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CXR on first admission.
Figure 2
Figure 2
ECG on admission.
Figure 3
Figure 3
CXR on second admission.
Figure 4
Figure 4
High resolution CT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organisation. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/
    1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 1990;380:2095–2128. - PMC - PubMed
    1. Gane E., Stedman C., Brunton C., et al. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand. New Zealand Medical Journal. 2014;127(1407):61–74. - PubMed
    1. Chung R. T., Davis G. L., Jensen D. M., et al. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954. doi: 10.1002/hep.27950. - DOI - PubMed
    1. Hagan L. M., Schinazi R. F. Best strategies for global HCV eradication. Liver International. 2013;33(1):68–79. doi: 10.1111/liv.12063. - DOI - PMC - PubMed

Publication types

LinkOut - more resources